Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Post-Therapeutic Tumor Losses of B-Cell Receptor Components CD20/CD19, a New Challenge in the Management of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Thomas Hueso, Jessy Alchidiac, Maria-Rosa Ghigna, Arnaud Pages, Cyril Quivoron, Camille Bigenwald, Loic Renaud, Cristina Castilla-Llorente, Alexandre Eeckhoutte, Serge Bologna, Veronique Morel, Vincent Delwail, Pierre Feugier, Catherine Thieblemont, Olivier Bernard, Peggy Dartigues, Christophe Massard, Vincent Ribrag, Jean-Marie Michot

Blood (2024) 144 (Supplement 1): 474.

https://doi.org/10.1182/blood-2024-203664

Published: 2024

Journal Articles

First Results of the Acsé Pembrolizumab Phase II in the Primary CNS Lymphoma (PCNSL) Cohort

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-141773

Published: 2020

Journal Articles

Is Molecular Characterization Useful for Targeted Therapy Orientation in Patients with Relapsed or Refractory DLBCL Included in Early Phase Clinical Trials?

Jean-Marie Michot, MD, Valérie Camara-Clayette, PhD, Cyril Quivoron, PhD, Alina Danu, MD, Julien Lazarovici, MD, David Ghez, MD PhD, Julien Rossignol, MD PhD, Capucine Baldini, MD, Patricia Martin-Romano, MD PhD, Clementine Sarkozy, MD PhD, Andrea Varga, MD, Helene Lecourt, Veronique Vergé, MD, Sophie Cotteret, MD PhD, Peggy Dartigues-Cuillères, MD, Christophe Massard, MD PhD, Vincent Ribrag, MD

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-136134

Published: 2020

Journal Articles

High Incidence of TP53 and Epigenetic Modifying Oncogenes Mutations in a Large Cohort of Patients Enrolled in Phase 1 Clinical Trials for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Cyril Quivoron, PhD, Jean-Marie Michot, MD, Valérie Camara-clayette, PhD, Alina Danu, MD, Julien Lazarovici, MD, Clementine Sarkozy, MD PhD, David Ghez, MD PhD, Julien Rossignol, MD PhD, Capucine Baldini, MD, Patricia Martin-Romano, MD PhD, Helene Lecourt, Veronique Vergé, MD, Andrea Varga, MD, Sophie Cotteret, MD PhD, Peggy Dartigues-Cuillères, MD, Christophe Massard, MD PhD, Vincent Ribrag, MD

Blood (2020) 136 (Supplement 1): 10–11.

https://doi.org/10.1182/blood-2020-136114

Published: 2020

Journal Articles

Comparative Study of Tumor Biopsy and Ctdna to Support Patient Selection in Phase I Trials: The Gustave Roussy Single Center Experience in Aggressive B-Cell Lymphomas

Anthony Tarabay, MD, Jean-Marie Michot, MD, Anne Aupérin, Julien Lazarovici, Julien Rossignol, MD PhD, David Ghez, MD PhD, Peggy Dartigues-Cuillères, MD, Veronique Vergé, Vincent Ribrag, MD, Christophe Massard, Valérie Camara-clayette

Blood (2019) 134 (Supplement_1): 1496.

https://doi.org/10.1182/blood-2019-127170

Published: 2019

Journal Articles

Outcomes of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Included in Phase I Clinical Trials

Marion Brault, Maxime Annereau, PharmD, Alina Danu, MD, Julien Lazarovici, MD, Claude Chahine, MD, Andrea Varga, Capucine Baldini, Stéphane Champiat, Malik Berhoune, Christophe Massard, François Lemare, Vincent Ribrag, MD, Jean-Marie Michot, MD

Blood (2018) 132 (Supplement 1): 2992.

https://doi.org/10.1182/blood-2018-99-112919

Published: 2018

Journal Articles

Feasibility and Benefit of Molecularly-Informed Enrollment into Early Phase Clinical Trials for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Blood (2018) 132 (Supplement 1): 4110.

https://doi.org/10.1182/blood-2018-99-110852

Published: 2018

Journal Articles

Immunological Cytopenias Induced By Anti-Programmed Cell Death (ligand) 1 Antibodies

Blood (2018) 132 (Supplement 1): 2412.

https://doi.org/10.1182/blood-2018-99-110875

Published: 2018

Journal Articles

Feasibility and Benefit of Molecularly-Informed Enrollment into Personalized Therapies or Early Phase Trials for Patients with Relapsed or Refractory Multiple Myeloma

Tarek Assi, Jean-Marie Michot, MD, Toni Ibrahim, MD MSc, Fabien Le Bras, Karim Belhadj, Julien Lazarovici, MD, David Ghez, MD PhD, Julien Rossignol, MD PhD, Veronique Vergé, Julia Arfi-Rouche, Sophie Cotteret, Christophe Massard, Jean-Charles Soria, Alina Danu, MD, Vincent Ribrag, MD

Blood (2018) 132 (Supplement 1): 2001.

https://doi.org/10.1182/blood-2018-99-111050

Published: 2018

NARROW

Post-Therapeutic Tumor Losses of B-Cell Receptor Components CD20/CD19, a New Challenge in the Management of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

First Results of the Acsé Pembrolizumab Phase II in the Primary CNS Lymphoma (PCNSL) Cohort

Is Molecular Characterization Useful for Targeted Therapy Orientation in Patients with Relapsed or Refractory DLBCL Included in Early Phase Clinical Trials?

High Incidence of TP53 and Epigenetic Modifying Oncogenes Mutations in a Large Cohort of Patients Enrolled in Phase 1 Clinical Trials for Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Comparative Study of Tumor Biopsy and Ctdna to Support Patient Selection in Phase I Trials: The Gustave Roussy Single Center Experience in Aggressive B-Cell Lymphomas

Outcomes of Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Included in Phase I Clinical Trials

Feasibility and Benefit of Molecularly-Informed Enrollment into Early Phase Clinical Trials for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Immunological Cytopenias Induced By Anti-Programmed Cell Death (ligand) 1 Antibodies

Feasibility and Benefit of Molecularly-Informed Enrollment into Personalized Therapies or Early Phase Trials for Patients with Relapsed or Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only